Adjunctive long-term use of Mucinex® leading to improvement in stable chronic bronchitis and patient’s quality of life: A case report

We describe a case of a chronic obstructive pulmonary disease patient with stable chronic bronchitis who experienced improved quality of life and reduced symptoms during daily long-term Mucinex® (extended-release guaifenesin) use. Through a validated patient-reported outcome, the cough and sputum assessment questionnaire (CASA-Q), cough impact and symptoms scores showed improvements of 37.5 and 50 points, respectively, at week 11 compared to baseline. Similarly, sputum impact and symptoms scores improved by 37.5 and 41.7 points. While these observations support a potential benefit of adjunctive mucoactive therapy in chronic respiratory conditions, they should be interpreted cautiously and considered hypothesis-generating, highlighting the need for further controlled studies.

Authors

Institutions

Publication Details

Journal
Medical Reports
Published
2025-10-17
DOI
https://doi.org/10.1016/j.hmedic.2025.100384
Primary Topic
Respiratory and Cough-Related Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adjunctive long-term use of Mucinex® leading to improvement in stable chronic bronchitis and patient’s quality of life: A case report

Oktawia Borecka, Samuel Llewellyn, Selwyn Spangenthal, Connie Divel
Medical Reports
Respiratory and Cough-Related Research
article

Adjunctive long-term use of Mucinex® leading to improvement in stable chronic bronchitis and patient’s quality of life: A case report

Oktawia Borecka, Samuel Llewellyn, Selwyn Spangenthal, Connie Divel
article en

Abstract

We describe a case of a chronic obstructive pulmonary disease patient with stable chronic bronchitis who experienced improved quality of life and reduced symptoms during daily long-term Mucinex® (extended-release guaifenesin) use. Through a validated patient-reported outcome, the cough and sputum assessment questionnaire (CASA-Q), cough impact and symptoms scores showed improvements of 37.5 and 50 points, respectively, at week 11 compared to baseline. Similarly, sputum impact and symptoms scores improved by 37.5 and 41.7 points. While these observations support a potential benefit of adjunctive mucoactive therapy in chronic respiratory conditions, they should be interpreted cautiously and considered hypothesis-generating, highlighting the need for further controlled studies.

Medical ReportsVol. 14
American Health Research Institute (US)
Openalex Percentile: Top 58%
Respiratory and Cough-Related Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.